Determining clinically meaningful decline in preclinical Alzheimer disease

episode

Neurology® Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Pretty Little Episode #110 26 min · 25 Sep 2026 · Handsome

Ireland collapse in Kosovo as Israel game looms 13 min · 25 Sep 2026 · Today with David McCullagh

Living Breakthrough-Minded | Joel Osteen 30 min · 25 Sep 2026 · Joel Osteen Podcast

4AM ET 09/25/2026 Newscast 3 min · 25 Sep 2026 · Fox News Hourly Update

The Week: Trump vs the Press, Meta’s AI Win, and the Turning Political Tide 22 min · 25 Sep 2026 · The Prof G Pod with Scott Galloway

Gabrielle Lyon Part 2 1h 1m · 25 Sep 2026 · unPAUSED with Dr. Mary Claire Haver

Report any issue

Source

Recorded22 Jul 2019

Publisherneurology.libsyn.com ↗

Handlerec:5447918

Show notes

In the first segment, Dr. Gregory Day talks with Dr. Philip Insel about his paper on determining clinically meaningful decline in preclinical Alzheimer disease. In the second part of the podcast, Dr. Sarah Tabrizi talks about targeting Huntington expression in patients with Huntington's disease in her interview with Dr. Jeffrey Ratliff. Read Dr. Tabrizi's paper in NEJM: https://www.nejm.org/doi/full/10.1056/NEJMoa1900907?query=recirc_curatedRelated_article.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in